Story
Trump Administration Nears Drug Pricing Deals with Biotech Firms for Medicaid, Report Says

The Trump administration plans to announce drug-pricing agreements with several midsized biotech companies, according to a Bloomberg report citing people familiar with the matter. The deals would reportedly involve the companies providing discounts on outpatient drugs to state Medicaid programs.
Details of the Agreements
Under the terms being discussed, the participating companies would agree to align the prices that state Medicaid programs pay with the lower prices they charge in certain foreign countries. This model is often referred to as a "most-favored-nations" approach. In exchange for offering these discounts, the drugmakers would receive key incentives:
- Exemption from pilot programs that would force similar discounts within the Medicare system.
- Potential relief from tariffs, which has been part of some discussions, according to the sources.
Participation in this new pricing model would be optional for state Medicaid programs.
Market Impact and Unanswered Questions
AdThe financial impact of these potential agreements remains uncertain. It is not yet clear how much the deals would save the federal government or the low-income and disabled patients covered by Medicaid. The names of the specific biotech companies involved have also not been disclosed.
Analysts note that Medicaid already receives substantial, legally mandated discounts from pharmaceutical manufacturers, and patients in the program typically have very low out-of-pocket costs for prescriptions. These existing conditions could limit the incremental savings generated by the new voluntary agreements.
White House Acknowledges Negotiations
While declining to confirm a specific announcement, White House spokesman Kush Desai told Bloomberg that "the Trump administration continues to make great progress negotiating additional most-favored-nations deals to cut drug costs for American patients."
Desai added that any specific deals or events should be considered speculation until they are officially announced by the administration, according to the report.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.